Cannabis and Mental Health: Why the Evidence Looks So Contradictory—and What Actually Matters
Clinicians often face cannabis mental health contradictions in research findings. These contradictions arise from varying THC and CBD effects and individual patient factors. Understanding these contradictions is key for evidence-based clinical decisions.
Psychedelic Drug Clinical Trials Update – April 2026
This update covers recent developments in psychedelic drug clinical trials relevant to cannabis clinicians. The focus is on accelerating research and patient access in 2026. These insights help clinicians navigate evolving psychoactive substance policies.
President Trump Signs Executive Order Encouraging Psychedelic Research
The psychedelic executive order research marks a significant shift in federal policy encouraging clinical trials on psychedelic drugs. This change aims to reduce regulatory barriers and accelerate research on treatment-resistant psychiatric conditions.…
Understanding Cannabis Use Disorder – Addiction Policy Forum
Cannabis use disorder clinical relevance is critical as it affects about 9% of users but remains underdiagnosed. This condition involves withdrawal symptoms and functional impairment. Effective screening and treatment approaches are essential for better…
Trump Accelerates Psychedelic Drug Research to Aid Veterans
Federal policy changes are accelerating psychedelic drug research veterans to improve treatment timelines. This focus on veterans aims to bring MDMA and psilocybin therapies closer to clinical use. The research targets treatment-resistant PTSD and…
Trump Signs Order To Accelerate Legal Access To Psychedelic Therapies For Mental Health
The recent executive order aims to accelerate psychedelic-assisted therapies mental health access, potentially transforming treatment for resistant depression and PTSD. This policy shift could open new pathways for patients who have not responded to…
Trump Set to Ease Restrictions on Psychedelic Drug for PTSD
Psychedelic drug policy developments are shaping the future of PTSD treatment. Regulatory easing could improve patient access to FDA-approved therapies. Clinicians should monitor these changes closely for clinical implications.
Trump Plans Psychedelic Executive Order (Newsletter: April 17, 2026)
The 2026 psychedelic drug policy developments could reshape access to psilocybin and MDMA treatments currently in FDA trials. These changes matter clinically for patients with PTSD and depression. Clinicians should monitor these developments closely for…
Many will judge me, but cannabis controls my anxiety
Cannabis clinical stigma remains a barrier despite many patients using it to control anxiety. This article highlights personal experiences and clinical insights into cannabis for anxiety. Understanding stigma helps improve patient access and informed…
High-Potency Cannabis: America’s New Pastime and Psychiatry’s Next Challenge
High-potency THC products dominate the US cannabis market, posing new challenges for psychiatry. These products require updated dosing guidelines and harm reduction strategies. Understanding high-potency THC products is essential for clinical assessment…
